EUROPE NEWBORN SCREENING MARKET 2019-2027

MARKET OUTLOOK
Triton Market Research has envisioned the Europe newborn screening market to witness a CAGR of 13.42% over the forecasting period of 2019-2027.
The United Kingdom, France, Spain, Germany, Russia, Italy and countries in rest of Europe together constitute the market for newborn screening in the European region.
The rise of the newborn screening market in France is backed by the government’s mandatory regulation supporting newborn screening, and according to the French Association for the Screening and Prevention of Child Handicaps (France). France mandates and regulates newborn screening for five congenital diseases such as sickle cell anemia, phenylketonuria, cystic fibrosis, congenital adrenal hyperplasia and congenital hypothyroidism. Additionally, these newborn screening activities are financed by the National Public Health Insurance with a motive to provide education on newborn screening on newborn screening on blood spots and to raise the adoption of newborn screening activities in France. Due to the government mandate on newborn screening, the adoption of newborn screening would rise, which positively influences the growth of the newborn screening market in France. Furthermore, as per France’s National Institute of Statistics and Economics Studies (INSEE), France had the highest birth rate in Europe, which was around 1.96 children per woman; and the need for newborn screening would rise, considering the many complications that a premature newborn would experience, which positively influences the growth of the country’s newborn screening market.
COMPETITIVE OUTLOOK
The biggest brands in the market are Medtronic Plc, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., BioTek Instruments, Inc., Masimo Corporation, Agilent Technologies, Inc., NeoGen Labs Pvt. Ltd., Waters Corporation, PerkinElmer, Inc., Natus Medical, Incorporated, SCIEX, Trivitron Healthcare, ZenTech S.A., Cardinal Health, Inc. and GE Healthcare Limited.

TABLE OF CONTENT
1. EUROPE NEWBORN SCREENING MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. DEMAND FOR NEWBORN SCREENING INSTRUMENTS IS RISING STEADILY
2.2.2. GROWTH IN DRY BLOOD SPOT TEST
2.2.3. TECHNIQUES USED IN NEWBORN SCREENING TESTS
2.3. EVOLUTION & TRANSITION OF NEWBORN SCREENING
2.4. PORTER’S FIVE FORCE ANALYSIS
2.4.1. THREAT OF NEW ENTRANTS
2.4.2. THREAT OF SUBSTITUTE
2.4.3. BARGAINING POWER OF SUPPLIERS
2.4.4. BARGAINING POWER OF BUYERS
2.4.5. THREAT OF COMPETITIVE RIVALRY
2.5. KEY IMPACT ANALYSIS
2.5.1. RELIABILITY
2.5.2. COST
2.5.3. AVAILABILITY
2.5.4. TECHNOLOGICAL ADVANCEMENT
2.6. MARKET ATTRACTIVENESS INDEX
2.7. VENDOR SCORECARD
2.8. INDUSTRY COMPONENTS
2.8.1. RAW MATERIAL SUPPLIERS
2.8.2. MANUFACTURERS
2.8.3. DISTRIBUTORS
2.8.4. END-USERS
2.9. REGULATORY FRAMEWORK
2.10. INDUSTRY PLAYER POSITIONING
2.11. KEY MARKET STRATEGIES
2.11.1. PRODUCT LAUNCH
2.12. MARKET DRIVERS
2.12.1. INCREASE IN OCCURRENCES OF NEWBORN DISEASES
2.12.2. GROWING NUMBER OF INFANTS WITH BIRTH DEFECT
2.12.3. BACKING OF GOVERNMENT TOWARDS NEWBORN CHILD HEALTH
2.12.4. RISING AWARENESS FOR PEDIATRIC CONGENITAL HEART DISEASE
2.13. MARKET RESTRAINTS
2.13.1. SOCIO-ECONOMIC HURDLES IN THE IMPLEMENTATION OF NEWBORN CHILD SCREENING
2.14. MARKET OPPORTUNITIES
2.14.1. NEWBORN SCREENING HELPS IN EARLY IDENTIFICATION AND MANAGEMENT OF AFFECTED NEWBORNS
2.14.2. TECHNOLOGICAL ADVANCEMENTS IN NEWBORN SCREENING
2.14.3. INCREASE IN NUMBER OF PREGNANT WOMEN WITH ADVANCED MATERNAL AGE
2.15. MARKET CHALLENGES
2.15.1. DEARTH OF SKILLED PROFESSIONAL IN HEALTHCARE INDUSTRY
2.15.2. MAINTENANCE OF EQUIPMENT IN HOSPITAL
3. NEWBORN SCREENING MARKET OUTLOOK - BY PRODUCT
3.1. NEWBORN SCREENING INSTRUMENTS
3.2. NEWBORN SCREENING REAGENTS & ASSAY KITS
4. NEWBORN SCREENING MARKET OUTLOOK - BY TEST TYPE
4.1. HEARING SCREEN TEST
4.2. CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST
4.3. DRY BLOOD SPOT TEST
5. NEWBORN SCREENING MARKET OUTLOOK - BY TECHNOLOGY
5.1. TANDEM MASS SPECTROMETRY
5.2. PULSE OXIMETRY
5.3. ENZYME-BASED ASSAYS
5.4. DNA-BASED ASSAYS
5.5. ELECTROPHORESIS
5.6. OTHERS
6. NEWBORN SCREENING MARKET - REGIONAL OUTLOOK
6.1. UNITED KINGDOM
6.2. GERMANY
6.3. FRANCE
6.4. SPAIN
6.5. ITALY
6.6. RUSSIA
6.7. REST OF EUROPE
7. COMPETITIVE LANDSCAPE
7.1. SCIEX
7.2. BIOTEK INSTRUMENTS, INC.
7.3. BIO-RAD LABORATORIES, INC.
7.4. CARDINAL HEALTH, INC.
7.5. GE HEALTHCARE LIMITED
7.6. AGILENT TECHNOLOGIES, INC.
7.7. MASIMO CORPORATION
7.8. NATUS MEDICAL, INCORPORATED
7.9. MEDTRONIC PLC
7.10. THERMO FISHER SCIENTIFIC, INC.
7.11. NEOGEN LABS PVT. LTD.
7.12. PERKINELMER, INC.
7.13. ZENTECH S.A.
7.14. WATERS CORPORATION
7.15. TRIVITRON HEALTHCARE
8. METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY


LIST OF TABLES
TABLE 1: EUROPE NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: REGULATORY FRAMEWORK
TABLE 5: LIST OF PRODUCT LAUNCHES
TABLE 6: EUROPE NEWBORN SCREENING MARKET, BY PRODUCT, 2019-2027 (IN $ MILLION)
TABLE 7: EUROPE NEWBORN SCREENING MARKET, BY TEST TYPE, 2019-2027 (IN $ MILLION)
TABLE 8: EUROPE NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2019-2027 (IN $ MILLION)
TABLE 9: EUROPE NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: KEY BUYING IMPACT ANALYSIS
FIGURE 3: INDUSTRY COMPONENTS
FIGURE 4: INDUSTRY PLAYER POSITIONING IN 2018 (IN %)
FIGURE 5: FERTILITY RATE (AVERAGE BIRTHS PER WOMAN IN %) IN 2017
FIGURE 6: EUROPE NEWBORN SCREENING MARKET, BY NEWBORN SCREENING INSTRUMENTS, 2019-2027 (IN $ MILLION)
FIGURE 7: EUROPE NEWBORN SCREENING MARKET, BY NEWBORN SCREENING REAGENTS & ASSAY KITS, 2019-2027 (IN $ MILLION)
FIGURE 8: EUROPE NEWBORN SCREENING MARKET, BY HEARING SCREEN TEST, 2019-2027 (IN $ MILLION)
FIGURE 9: EUROPE NEWBORN SCREENING MARKET, BY CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST, 2019-2027 (IN $ MILLION)
FIGURE 10: EUROPE NEWBORN SCREENING MARKET, BY DRY BLOOD SPOT TEST, 2019-2027 (IN $ MILLION)
FIGURE 11: EUROPE NEWBORN SCREENING MARKET, BY TANDEM MASS SPECTROMETRY, 2019-2027 (IN $ MILLION)
FIGURE 12: EUROPE NEWBORN SCREENING MARKET, BY PULSE OXIMETRY, 2019-2027 (IN $ MILLION)
FIGURE 13: EUROPE NEWBORN SCREENING MARKET, BY ENZYME-BASED ASSAY, 2019-2027 (IN $ MILLION)
FIGURE 14: EUROPE NEWBORN SCREENING MARKET, BY DNA-BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 15: EUROPE NEWBORN SCREENING MARKET, BY ELECTROPHORESIS, 2019-2027 (IN $ MILLION)
FIGURE 16: EUROPE NEWBORN SCREENING MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 17: EUROPE NEWBORN SCREENING MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
FIGURE 18: UNITED KINGDOM NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 19: GERMANY NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 20: FRANCE NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 21: SPAIN NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 22: ITALY NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 23: RUSSIA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 24: REST OF EUROPE NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)